Comparative analysis of the effectiveness of Botulinum toxin type A — hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm

Gusev V.V.; Makarov E.A.; Lvova O.A.

doi:https://doi.org/10.17116/jnevro202512502186

Gusev V.V.

Ural State Medical University;
Ural Federal University named after the first President of Russia B.N. Yeltsin

ORCID: 0000-0003-2232-7074

Makarov E.A.

Ural State Medical University

ORCID: 0009-0000-8477-2742

Lvova O.A.

Ural State Medical University;
Ural Federal University named after the first President of Russia B.N. Yeltsin

ORCID: 0000-0002-2280-3096

Comparative analysis of the effectiveness of Botulinum toxin type A — hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm

Authors:

Gusev V.V., Makarov E.A., Lvova O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2): 86‑90

DOI: 10.17116/jnevro202512502186

Read: 1330 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gusev VV, Makarov EA, Lvova OA. Comparative analysis of the effectiveness of Botulinum toxin type A — hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):86‑90. (In Russ.)
https://doi.org/10.17116/jnevro202512502186

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To analyze the effectiveness of Relatox (Botulinum toxin type A — hemagglutinin complex) in comparison with Botox in the treatment of primary idiopathic blepharospasm.

MATERIAL AND METHODS

The study included clinical data for 21 patients with blepharospasm who were treated by botulinum therapy with Botox and Relatox for 3 years. The research method is a one-step retrospective analysis of medical data. Injections were carried out with a 3-month interval. On the 6th cycle, the drug was switched to Relatox. The clinical efficacy of the drugs was assessed using an 8-point Jankovich evaluation scale: the average values before the injection and 14 days after it were compared for each procedure.

RESULTS

Mean Jankovich scale scores decreased 2.5-fold for all cycles by the second week after the procedure (4.95 pre-injection vs. 1.8 post-injection), and the mean paired Student’s T-criterion for all injections was 7.14 (with a critical value of 2.021 and a significance level of p=0.05). The mean paired Student’s T-criterion for Botox was –6.63 and for Relatox –7.5 (with a critical value of 2.021 and a significance level of p=0.05), indicating a high efficacy of both drugs, slightly higher for Relatox.

CONCLUSION

A consistent trend of increasing efficacy with regular botulinum toxin injections and greater efficacy of Relatox compared to Botox in the treatment of patients with primary idiopathic blepharospasm has been demonstrated.

Keywords:

Primary idiopathic blepharospasm

botulinum therapy

Relatox

Botox

Yankovich scale

Authors:

Gusev V.V.

Ural State Medical University;
Ural Federal University named after the first President of Russia B.N. Yeltsin

ORCID: 0000-0003-2232-7074

Makarov E.A.

Ural State Medical University

ORCID: 0009-0000-8477-2742

Lvova O.A.

Ural State Medical University;
Ural Federal University named after the first President of Russia B.N. Yeltsin

ORCID: 0000-0002-2280-3096

Received:

30.01.2025

Accepted:

18.02.2025

Close metadata

References:

Defazio G, Hallett M, Jinnah HA, et al. Blepharospasm 40 years later. Mov Disord. 2017;32(4):498-509. https://doi.org/10.1002/mds.26934
Hassell TJW, Charles D. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. Toxins. 2020;12(4):269-275. https://doi.org/10.3390/toxins12040269
Dystonia. Clinical guidelines. 2024. (In Russ.).
Gamain J, Herr T, Fleischmann R, et al. Smell and taste in idiopathic blepharospasm. J Neural Transm (Vienna). 2021;128(8):1215-1224. https://doi.org/10.1007/s00702-021-02366-4
Jankovic J, Kenney C, Grafe S, et al. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407-413. https://doi.org/10.1002/mds.22368
Kilic-Berkmen G, Defazio G, Hallett M, et al. Diagnosis and classification of blepharospasm: Recommendations based on empirical evidence. J Neurol Sci. 2022;439:120319. https://doi.org/10.1016/j.jns.2022.120319
Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. https://doi.org/10.3410/f.726345042.793519461
Artemenko AR, Kurenkov AL, Belomestova KV. On the absence of interchangeability of botulinum toxin type A drugs. Medical Sovet. 2015;5:112-123. (In Russ.).
Roggenkämper P, Jost WH, Bihari K, et al; NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006;113(3):303-312. https://doi.org/10.1007/s00702-005-0323-3
https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3e682ada-5ea7-4782-aacd-a07f2787d820 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3e682ada-5ea7-4782-aacd-a07f2787d820
https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=857bb5b2-f69e-4462-9b2d-b92ad0f2659e https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=857bb5b2-f69e-4462-9b2d-b92ad0f2659e